Skip to main content

Effect of anticoagulants on binding and neutralization of lipopolysaccharide by the peptide immunoglobulin conjugate CAP18(106-138)-immunoglobulin G in whole blood.

Ogata M, Fletcher MF, Kloczewiak M, Loiselle PM, Zanzot EM, Vermeulen MW, Warren HS

Publication: Infect Immun (1997) • Vol 65 • Page 2160-7PMID: 9169746View on PubMed

Purpose

The purpose of this paper was to determine the effects of use and type of anticoagulant on the ability of CAP18(106-138)-immunoglobulin G (IgG) to bind to and inhibit lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) production in whole blood.

Conclusion

In whole blood without any anticoagulant, CAP18(106-138) and CAP18(106-138)-IgG inhibited LPS-induced TNF production. This inhibition was enhanced when EDTA was present and was blocked when heparin was present, each in dose dependent manners.

Studies (1)

Purpose

The purpose of this study was to determine the effects of use and type of anticoagulant on the ability of CAP18(106-138)-IgG to inhibit LPS-induced TNF production in whole blood. Blood was collected into syringes containing EDTA, heparin, or no anticoagulant, diluted with HBSS, transferred to tissue culture plates, and CAP18(106-138) with or without the IgG conjugate was added along with LPS. After incubation of blood for 4 h at 37 degrees C, specimens were centrifuged and frozen at -80 degrees C until they were assayed for TNF.

Summary of Findings

In whole blood without any anticoagulant, CAP18(106-138) and CAP18(106-138)-IgG inhibited LPS-induced TNF production. This inhibition was enhanced when EDTA was present and was blocked when heparin was present, each in dose dependent manners.
  • Biospecimens

    FluidBlood
  • Preservation Types

    Frozen
  • Diagnoses

    Not specified
  • Platforms

    ProteinELISA
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionAnticoagulant
    EDTA
    Heparin
    Multiple concentrations evaluated
    None